Controversy in clinical endocrinology: reclassification of insulin-like growth factor I production and action disorders.
BACKGROUND
The need for the least ambiguous terminology for disorders affecting IGF-I production and action has become necessary with identification of defects at various steps in the GH-IGF-I axis and the promotion of new indications for and modalities of growth therapy. No generally agreed-upon or consensus-derived classification exists.


OBJECTIVE
Our objective was to designate all disorders affecting IGF-I production and action by their discrete location, as is already done with the defects in pituitary differentiation factors, avoiding imprecise and ambiguous terminology.


CONCLUSIONS
We propose a pragmatic classification that is a precise listing of specific disorders sequentially following the GH-IGF-I axis, using their accepted designations, and the abolition of nonspecific or ambiguous terminology. This concept permits ready insertion of new discoveries.
Rosenbloom
Arlan L
AL
Division of Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida 32608, USA. rosenal@peds.ufl.edu
Guevara-Aguirre
Jaime
J
D004704:Endocrinology / Q000379:methods* / Q000639:trends; D006130:Growth Disorders / Q000145:classification; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis* / Q000172:deficiency* / Q000378:metabolism*; D008661:Metabolism, Inborn Errors / Q000145:classification* / Q000209:etiology; D009626:Terminology as Topic
D007334:Insulin-Like Growth Factor I